Bristol-Myers Squibb: "Bristol-Myers right now does not have what we're looking for in terms of that cancer franchise that's going to Merck. I've got to tell you, down here, with a 3 percent yield, it gets attractive. But because of interest rates going higher, I'm going to have to take a pass for the moment.
"Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться